Purpose: This review will address the current state of individualized cancer therapy for glioblastoma. Glioblastomas are highly malignant primary brain tumors presumably originating from neuroglial progenitor cells. Median survival is less than 1 year.
By High-Throughput Analysis
Beyond morphology, an increasing number of publications used high-throughput techniques to derive a subclassification of glioblastomas. One model of molecular classification based on gene expression analyses was proposed by Phillips et al. 2 Selecting a set of genes associated with survival in their patient cohort enriched for long-term survivors (92 years), they identified 3 glioblastoma subtypes with distinct molecular signatures, which they termed proneural, proliferative, and mesenchymal. The proneural signature is associated with oligodendroglial morphology, younger age, lack of phosphatase and tensin homolog on chromosome ten (PTEN) or epidermal growth factor receptor (EGFR) abnormalities, activation of the Notch pathway, and better outcome. The proliferative and mesenchymal signatures are more common in older patients and are characterized by PTEN loss and Akt pathway activation and have a less favorable outcome. They are distinguished by a preponderance of either proliferation or angiogenesis. Verhaak et al 3 took an unsupervised approach, extracting gene expression patterns that yielded 4 molecular signatures for glioblastoma, which they termed proneural, neural, classic, and mesenchymal subtypes, in allusion to similarities with signatures of the classification proposed by Phillips et al. 2 These subtypes also segregate the characteristic mutations. The proneural subtype comprises most isocitrate dehydrogenase (IDH) 1 mutations and is enriched for p53 mutations, whereas the classic subtype particularly enriches for EGFR-amplified tumors expressing also the EGFRvIII variant. The mesenchymal subtype contains most neurofibromatosis (NF )-1-mutant tumors. Hence, the expression subtypes overlap with major previously identified pathogenetic pathways involved. Of note, O 6 -methylguanine methyltransferase (MGMT) promoter methylation is not particularly enriched in any specific subtype. The authors proposed that patients with classic or mesenchymal glioblastoma derive more benefit from aggressive treatment, but this requires confirmation within a prospective clinical trial.
Other approaches set out to identify gene signatures characterizing cancer-relevant biological features using unsupervised approaches. This, among others, has yielded a stem cellYrelated gene expression signature dominated by HOX genes that was a predictor of failure from the addition of temozolomide to radiotherapy, independent of the MGMT status. 4 This signature was thereafter independently identified in pediatric glioblastoma, tumors that are otherwise quite different from their adult counterparts. Interestingly, the HOX gene signature predicted failure from temozolomide therapy independent of MGMT. 5 Another view on the biology of tumors is provided by analyzing microRNAs that have regulatory functions. microRNA expression profiles yielded biologically meaningful subclassification of glioblastomas, for which 5 subclasses have been proposed using the Cancer Genome Atlas data that relate to developmental patterns. 6 Three of these overlap substantially with 3 of the 4 subclasses based on the gene expression classification of Veerhak et al. 3 Yet another approach to characterize tumors is to evaluate aberrant DNA methylation at CpG sites that denote a major mechanism of epigenetically controlled silencing of genes including noncoding RNAs, such as microRNAs. Noushmehr et al 7 assessed DNA methylation at 27K CpG sites in 272 glioblastomas of the Cancer Genome Atlas and observed several methylation subtypes of which 1 subgroup exerted a striking pattern of concerted hypermethylation consistent with the delineation of a glioma-CpG island methylator phenotype now commonly referred to as G-CIMP. The G-CIMP phenotype characterizes a subgroup of tumors with the proneural signature and is closely associated with IDH mutations (see below) and is associated with good prognosis. In glioblastoma, G-CIMP is associated with secondary glioblastoma, arising from lowergrade lesions. 8 Hence not surprising, G-CIMP is also common in grade 2 and grade 3 glioma with strong association with IDH mutations. Screening for IDH mutations will identify most G-CIMPYpositive gliomas. 7 The recently presented molecular data from the Radiation Therapy Oncology Group 0525/ European Organization for Research and Treatment of Cancer 26052 glioblastoma trial support this view. G-CIMP only added an insignificantly different intermediate group to the highly correlating IDH1-mutated or G-CIMP-favorable group versus the IDH1-wild-type/G-CIMPYunfavorable group. 9 However, a recent study in anaplastic glioma suggested that G-CIMP outperforms IDH1 mutations as a prognostic biomarker, although IDH2 mutations were not determined. 10 The availability of genome-wide methylation analysis provides new opportunities to find new targets for personalized therapy or identify the ''Achilles heel'' of tumors, as previously described for the silencing of MGMT by promoter methylation that sensitizes tumors to alkylating agents (see below). 11, 12 Thus, at present, despite promising developments, no specific treatment recommendations can be derived from high-throughput approaches of molecular classification.
SUBCLASSIFYING GLIOBLASTOMA BY SINGLE MOLECULAR MARKERS P53
Mutations of the p53 gene or its downstream effector molecules are among the most common molecular aberrations in human cancers, including gliomas. 13, 14 Among glioblastomas, p53 mutations are more common in secondary glioblastomas and are thus associated with IDH mutation status. However, the p53 pathway in typical primary glioblastomas is also commonly disabled because glioblastoma cells do not readily undergo apoptosis when exposed to ionizing irradiation or DNA-damaging chemotherapy. There is thus no role for the p53 status in determining treatment decisions in glioblastoma. Promising efforts at exploiting p53 abnormalities are still being evaluated: p53 mutations may result in protein overexpression and give rise to novel immunogenic targets that might be used for vaccination therapy. 15 Moreover, it is likely that tumors with p53 mutations would be susceptible to efforts at reintroducing wild-type p53. This could be accomplished in the form of p53 gene therapy 16 or the development of new experimental agents, which restore an active conformation of p53, despite the mutation, and thereby transcriptional activity. Such agents exhibit profound antiglioma properties in vitro, but not of all of their activity could be linked strictly to the predicted effect on mutant p53 variants. 17, 18 EGFR Increased expression of the EGFR gene is common in glioblastoma, in particular in primary glioblastoma, and is thus inversely correlated with p53 and IDH mutations. Enhanced EGFR signaling may result from enhanced expression related to amplification or from mutational activation. Loss of exons 2 to 7 of the EGFR gene affects 801 base pairs and results in a mutant receptor (EGFRvIII) that is constitutively active in the absence of ligand binding. 19 Enhanced EGFR signaling activity promotes proliferation, invasiveness, and resistance to irradiation and chemotherapy. Extensive efforts at identifying responders to anti-EGFR treatment have not resulted in a uniform picture: Patients with high EGFR expression and low levels of phosphorylated Akt have been proposed to respond better to erlotinib than patients with tumors with low levels of EGFR expression and high levels of phosphorylated Akt. 20 Coexpression of EGFRvIII and PTEN was also reported to be associated with responsiveness to EGFR kinase inhibitors. 21 However, these observations were not confirmed in a prospective randomized trial comparing erlotinib with alkylating agent chemotherapy in recurrent glioblastoma. 22 A randomized trial of afatinib indicated inferior activity compared with reexposure to temozolomide, 23 and addition of erlotinib to combined chemoradiotherapy in newly diagnosed glioblastoma showed no promising results. 24 Several trials aiming at targeting the EGFR in glioblastoma patients have failed to demonstrate meaningful anti-tumor activity, although it was shown for gefitinib that high drug levels are reached in the tumor tissue, efficiently dephosporylating the EGFR, although without measurable effects on downstream targets. 25 Similar to p53, there is therefore currently no role for determining the EGFR status except that the detection of EGFR amplification or EGFRvIII mutation supports the diagnosis of glioblastoma in cases of doubt.
Nevertheless, targeting the EGFRvIII remains under investigation as a target for immunotherapy. Rindopepimut (CDX-110) is a vaccine product that consists of a 14-amino acid synthetic peptide built from 13 amino acids of EGFRvIII plus a cysteine residue, covalently linked to keyhole limpet hemocyanin as a carrier. This vaccine has been explored in phase II trials in patients with EGFRvIII-positive glioblastoma. Intriguingly, tumors progressing after vaccination therapy had commonly lost EGFRvIII expression, which is probably not the natural course of disease in standard treated EGFRvIII-positive glioblastoma, and responses on immune monitoring defined by antibody reactivity and delayed skin hypersensitivity were associated with better outcome. 26 In this very small trial, a progression-free survival of 14.2 months and median overall survival of 26.0 months were observed. This may simply reflect careful patient selection because vaccination was limited to patients who had undergone a gross tumor resection and had completed concomitant chemoradiotherapy without progression. The feasibility of performing a blinded, randomized trial to test the efficacy of this immunotherapeutic approach is currently being explored.
MGMT
MGMT has become the most promising and controversial biomarker in the field of glioblastoma. 11, 27 MGMT is a DNA repair protein that removes alkyl groups from DNA and is consumed by proteasomal degradation during that process. Its expression by cancer cells confers resistance to alkylating agent chemotherapy and may be a predictive factor for outcome in patients treated with such chemotherapy. Methylation of the MGMT promoter was strongly associated with benefit from combined chemotherapy and radiotherapy compared with radiotherapy alone in the registration trial for temozolomide in newly diagnosed glioblastoma. 28 A better outcome of patients with MGMT promoter methylation has been confirmed in numerous uncontrolled trials and retrospective analyses of glioblastoma patients treated with alkylating agents. However, a specific prediction of benefit of chemotherapy can only be deduced from data sets, which include a chemotherapy-free control arm like the initial temozolomide trial. Surprisingly, 2 randomized trials in patients with anaplastic gliomas containing radiotherapy only control arms reported the same degree of improved outcome in patients with MGMT promoter methylation irrespective of whether the patients were treated with radiotherapy alone or chemotherapy alone 29 or radiotherapy alone or radiotherapy plus nitrosourea-based chemotherapy. 30 Whether this is limiting the relevance of MGMT being predictive or just reflecting biological differences between anaplastic glioma and glioblastoma is currently investigated. The missing predictive impact in anaplastic glioma may be due to a retained allele of MGMT on the other arm of chromosome 10q or a strong association with the G-CIMP phenotype at least in anaplastic oligodendroglial tumors. 10 So far, these data support the view that anaplastic gliomas and glioblastomas are distinct entities that may be best separated by their IDH status (see below). 31 The MGMT status may assume greater relevance in elderly patients with glioblastoma where the efficacy of alkylating agent chemotherapy in addition to radiotherapy has not been demonstrated and where increased toxicity from combined modality treatment remains to be of concern and therefore the use of alkylating agents neither in the first-line or relapsed setting is standard-of-care. 32, 33 Whether temozolomide alone may be effective as radiotherapy alone in this setting remains unclear as long as complete data from 2 large randomized clinical trials are not available. The 3-arm Nordic trial that compared standard radiotherapy with hypofractionated radiotherapy and with temozolomide alone in 5 of 28-day cycles reported no difference between the treatment arms. 34 A preliminary report of the 2armed randomized NOA-08 trial that compared standard radiotherapy alone with dose-intensified temozolomide alone (1 week on 1 week off), failed to demonstrate noninferiority of dose-dense temozolomide. 35 A prospective, noninterventional cohort study of the German Glioma Network has identified a strong predictive value of MGMT promoter methylation for benefit from temozolomide: there was no evidence for benefit from alkylating agent chemotherapy in glioblastoma patients without MGMT promoter methylation whereas, conversely, there was an indication that temozolomide alone might be sufficient for patients with glioblastomas with MGMT promoter methylation. 36 Accordingly, the final results from the Nordic trial and NOA-08 need to be awaited and reassessed when data on outcome by MGMT status become available.
Much of the current discomfort of using MGMT as a biomarker results from the fact that it has been difficult to establish reliable testing procedures and to establish by consensus which test is best and how to perform it in detail. 27 Methylationspecific polymerase chain reaction remains to be the criterion standard, whereas more-expensive, less-readily available techniques such as pyrosequencing have not shown to be superior in correlating MGMT status with clinical outcome. The failure of MGMT protein assessment to correlate with MGMT promoter methylation and outcome has been extensively discussed and reviewed. 27, 37, 38 The S039 trial analyzing enzastaurin and radiotherapy in newly diagnosed non-MGMT methylated patients was the first trial that implemented MGMT status as an entry criterion. 39 The most extensive experience with MGMT as a biomarker has been made in the CENTRIC phase III trial that compared standard radiotherapy plus temozolomide with this standard plus the >MA 3/5 integrin antagonist cilengitide. On the basis of an uncontrolled phase II trial that indicated preferential benefit from cilengitide in patients with MGMT promoter methylation, 40 centralized upfront MGMT testing was introduced at study entry and enrolment restricted to patients with MGMT promoter methylation. While it remains unclear whether such an effort of patient selection was entirely justified for demonstrating efficacy of cilengitide, this trial, nevertheless, demonstrated the feasibility of molecular testing in large trials for patients with newly diagnosed glioblastoma.
IDH
The identification of somatic mutations of the IDH genes in most grade 2 and 3 gliomas as well as a minority of glioblastomas (G10%) was an important discovery of molecular neuropathology. 41, 42 The differential distribution of IDH mutations provides a strong rationale to consider grade 2/3 gliomas and glioblastomas as distinct tumor entities. IDH mutations are early events in gliomagenesis and are easy to determine using mutation-specific antibodies. The consistent mutational targeting of specific codons and the heterozygous nature of the mutations strongly suggest that mutant IDH proteins acquire a novel oncogenic activity that is only indirectly related to their physiologic function but results in the accumulation of a candidate oncometabolite, D 2 -hydroxyglutarate. Efforts at measuring this metabolite in peripheral blood of patients with IDH mutant gliomas were not successful so far, 43 but efforts at detection by magnetic resonance spectroscopy are under evaluation and may provide a noninvasive diagnostic tool to identify and monitor IDH-mutant gliomas. 44 The correlation of the neomorphic IDH mutants with G-CIMP has provided an interesting mechanistic hint: IDH1 or IDH2 mutations were also correlated with a methylator phenotype in leukemia. Furthermore, IDH1 and IDH2 mutations in leukemia were exclusive with TET2 mutations. It turned out that D-hydroxyglutarate inhibits TET2 that, in turn, is involved in DNA demethylation, 45 suggesting a functional link between IDH mutations, the development of a methylator phenotype, and TET2 function: metabolism meets epigenetics. Of note, it has not been demonstrated that this or any other metabolite maintains the neoplastic phenotype of gliomas once the tumors have been established. If this were the case, specific pharmacological targeting of the gain-of-function enzymatic activity of mutant IDH enzymes would be a highly promising targeted therapeutic approach, potentially devoid of adverse effects. In the absence of such approaches, determining the IDH status has diagnostic and (positive) prognostic impact but does not help to select among the current treatment options of radiotherapy versus chemotherapy versus combination thereof.
Angiogenesis
Inhibitors of angiogenesis are currently in the focus of drug development in glioblastoma. On the basis of uncontrolled phase II data, 2 agents with differential modes of action, the vascular endothelial growth factor antibody bevacizumab 46 and the RGD-mimetic >MA 3/5 integrin antagonist cilengitide 40 are being evaluated in phase III registration trials in patients with newly diagnosed glioblastoma, which have completed enrollment in 2011. Similar to traditional approaches to glioblastoma, there is significant heterogeneity in the response of glioblastoma patients to these novel agents, and predictive biomarkers would greatly aid in the selection of specific treatments, both for patient enrichment in clinical trials and in the future with a possible scenario where more than 1 antiangiogenic agent might be approved for glioblastoma. So far, efforts at defining either predictive soluble plasma markers or imaging parameters have not been successful, but promising approaches include the labeling of the target integrin of cilengitide by positron emission tomography 47 or the definition of the vascular normalization index consisting of vascular permeability (K trans ) and microvessel volume determined by magnetic resonance imaging and circulating collagen IV in plasma. 48 Extensive biomarker studies are accompanying most ongoing trials in the angiogenesis field.
Outlook
The perspectives of individualized treatment of glioblastoma depend on the identification and prospective evaluation of biomarkers that allow to predict a preferential benefit from a specific treatment, depending on the absence versus presence of this biomarker. To be clinically useful, the predictive biomarker needs to provide a clear segregation of patients into responders and nonresponders, and its evaluation should be based on reproducible, standardized test procedures. The usefulness of the best predictive biomarker we have at present, MGMT promoter methylation, is limited for these reasons. 27 EGFRvIII is currently a candidate biomarker that might be developed to meet these criteria, pending the demonstration of a test suitable for routine testing and clinical benefit from vaccination against EGFRvIII in a well-controlled clinical trial.
Further, it would be highly desirable if the targeted approach would target the most relevant cell populations within the tumor. Although the stem cell hypothesis has its weaknesses, there is, nevertheless, broad consensus that not all glioma cells within a tumor are alike, and features like spherogenicity, increased clonogenicity, multilineage differentiation potential, and tumorigenicity in rodents at low numbers of injected cells may well characterize a subpopulation of glioma cells that is responsible for resistance to therapy, progression, or relapse. However, no reliable stem cell marker has been defined in glioma cells so far, in particular no marker that would define a suitable target for molecular targeted therapy. Candidate pathways include, but are not limited to, the Notch pathway 49 and a HOX gene signature. 4 Carefully designed prospective trials are the only way to define a novel scenario where only patients with EGFRvIII mutation are vaccinated (if this vaccination is proven to be of benefit in the future), where only patients with MGMT promoter methylation receive temozolomide, where only integrin-positive patients by positron emission tomography will receive cilengitide (if this concept holds its promises), and where a novel biomarker has been established to predict which patient group benefits from bevacizumab. This chance should not be missed.
